Stomach Ache Problem

Takeda, Prometheus Enter IBD Drug-Companion Diagnostic Partnership

Prometheus Biosciences said its bioinformatics platform and advanced machine learning techniques will be used by Takeda Pharmaceutical as part of a global collaboration to...
These cramps are getting worse now

Gut Immune Cell Clock Genes Disruption Linked to IBD, Immune Control

Two independent sets of research published in Science Immunology have demonstrated how a subset of immune cells in the gut, known as group 3...

Cepheid’s BCR-ABL Test Gets FDA Approval

Cepheid announced that it has received clearance from the FDA for its Xpert BCR-ABL Ultra for monitoring disease burden in patients with chronic myeloid...

GRAIL’s New Blood-Based Cancer Screening Test Shows High Sensitivity and Specificity

Dana-Farber Cancer Institute researchers report the development of a new blood test that has shown the ability in a multi-center trial to screen for...
To make better use of genomics data

Illumina and the Broad Co-Developing Open-Source Secondary Analysis Software

Leading open-source tools, GATK and DRAGEN, are being combined to create a cutting-edge software suite for methods including small variant (SNV) and large variant...

In Conversation with Edward Abrahams, President, the Personalized Medicine Coalition

Edward Abrahams, Ph.D., has been president of the Personalized Medicine Coalition (PMC) since its founding in late 2004. After serving as an anchor partner...
Researchers at The University of Texas MD Anderson Cancer Center have found that a rare resistance mutation first thought to appear in melanoma (pictured) following treatment with a targeted therapy has instead turned out to be hiding in the tumor all along. [Definiens]

Melanoma Diagnosis Could be More Precise Using miRNA Biomarkers

Scientists headed by a team at the University of California, San Francisco (UCSF), now report on a new approach to diagnosing melanoma that uses...

NSIGHT2 Trial Finds No Difference in Diagnostic Rate Between WGS and WES

In a surprising result, a new clinical genomic trial in neonates in the NICU setting found no major difference in the diagnostic rate between...

Are Biomarkers in Semen the Future of Prostate Cancer Screening?

Semen could be considered a liquid biopsy of the organs of male reproductive system—specifically, of the prostate gland. This is convenient. Semen is, potentially,...

PGDx Applies CE Mark to Second Cancer Assay

Personal Genome Diagnostics (PGDx) said it has applied the CE mark to its PGDx elio tissue complete assay, a distinction the company said will enable...
Scroll Up